Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
The VitalDose Drug Delivery Platform has been used in patient-centric dose forms in women’s health for over two decades
Oteseconazole Capsules were found to be safe and more effective than fluconazole
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad
Abbott's multiplex test runs on its most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes – detecting four infections simultaneously
Subscribe To Our Newsletter & Stay Updated
